List of Small Molecule Pharmaceuticals Companies in Germany - 67

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S. patients annually, the first 30 days after diagnosis see persistently high mortality rates of 50-70%. Understand its pathophysiology, including the critical role of Dipeptidyl Peptidase 3, and the latest interventions.

AB Enzymes is an industrial biotech company specialized in enzymes and their applications. The company is part of Associated British Foods and represented worldwide. Our offices are located in Brazil, China Germany, Finland, Singapore and USA. Our products range from food grade enzymes for baking and beverages, grains and vegetable oil seeds processing, to enzymes for animal feed and technical applications: pulp & paper, textiles and laundry detergents. We partner with our diverse and unique customers to support them in their process optimization needs.

Acousia is a pioneer of novel medicines. Founded in 2012, the company’s experienced and entrepreneurial management team is committed to combating hearing loss. Thanks to its exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic and an ecosystem of experts and CROs, Acousia has made significant strides with its advanced small molecule drug candidates.

Personalised therapies for the heart and vasculature Innovative, independent, close to the patient. We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has been successfully tested in two Phase II studies. We work closely together with excellent academic and clinical teams in basic and clinical research. We use state-of-the-art analytical methods, and we develop our products according to the highest quality standards (GLP, GMP and GCP). Revacept is a therapeutic agent for the prevention and treatment of acute arterial thrombosis, which can lead to heart attack, acute limb ischemia and stroke. A Phase II clinical trial in 160 patients with stroke or transient ischaemic attack (TIA) has been completed. It showed beneficial effects in patients treated with 120 milligrams (mg) of Revacept. Another Phase II clinical trial investigated Revacept in 332 patients with stable coronary artery disease (ISAR-PLASTER) has been completed. This study conducted by the German Centre for Cardiovascular Research (DZHK) confirmed the very good tolerability of Revacept. Overall, Revacept did not lead to increased bleeding despite of its additional platelet aggregation inhibition on top of conventional standard therapy. It decreased ischemic strokes in NMR and improved the net clinical benefit of MACE and bleeding. Recently, the FDA has approved the preclinical and clinical development and the further phase 3 protocol until market approval. Antibody therapeutic In collaboration with Morphosys an anti-GPVI Fab antibody has been discovered. The candidate is currently in preclinical evaluation for the treatment of acute coronary syndrome and stroke. Imprint: https://www.advancecor.de/imprint/ privacy policy: https://www.advancecor.de/privacy-policy/

AiCuris (from 'Anti-infective Cures'​) is a pharmaceutical company focused on the discovery, research and development of novel antiviral agents for the treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients. Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris has a broad and innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

Aix Scientifics is a Contract Research Organisation that specializes in planning, implementing, and evaluating clinical research for pharmaceutical products and medical devices.

Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients.

Aptarion is dedicated to leveraging the strengths of biostable L-aptamers (highly specific "chemical antibodies") across the biomedical spectrum. Besides the discovery of new L-aptamers for the functionalization of sensors with its powerful platform technology, Aptarion pursues the development of its proprietary existing L-aptamers as therapeutics in areas of high medical need.

APURANO ist ein innovatives pharmazeutisches Unternehmen, das mit seiner weltweit patentierten Herstellungstechnologie PuranoTec® neuartige Nanoformulierungen entwickelt, die zur Behandlung verschiedener Krankheiten eingesetzt werden können. In 2023 führt APURANO die weltweit größten Phase III-Studien bei chronischen Schmerzen mit dem Arzneimittel Adezunap durch.

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company’s therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany.

To date, there are no approved drugs for the treatment of any sensorineural hearing loss disorder or tinnitus. At AudioCure Pharma we are determined to change this! Our vision is to turn incurable hearing loss into a treatable event. We are dedicated to the development of drug treatments for hearing disorders with a high unmet medical need. We have identified a new method of protecting and restoring the cellular key players that are critical to the hearing process. Therefore, our therapeutic approach goes beyond treating symptoms as we tackle the root cause of the disorders. Having successfully demonstrated preclinical proof of concept, our front-runner compound is currently in late stage preclinical development for the treatment of hearing loss. AudioCure is located in the vibrant capital of Germany, Berlin. Our offices are part of a cluster of high-tech companies and universities at the heart of the city. We are a team of highly skilled scientists and executives with a tight-knit network of academic partners, internationally renowned advisors and strategic investors. We also have close ties to the Charité University.

At baseclick GmbH we believe that bioconjugation is not just a method to connect (bio)molecules, but a tool to develop valuable applications. So, a new strategy was needed: click chemistry! " Nobel Prize 2022, the basis of the baseclick patented nucleic acid modification technology". We are a dynamic, highly professional team and enabling life science researchers to overcome challenges and create better solutions in diagnostics, therapeutics, and vaccines development through our proprietary click chemistry. Our mission is to develop and provide the best nucleic acid labeling applications and reagents for the life science market. For further information please visit our website https://www.baseclick.eu/ https://www.baseclick.eu/our-vaccine-strategy-and-its-benefits/

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power. Our products help address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. In line with our mission “Bayer: Science For A Better Life,” we aim to improve people’s quality of life by preventing, alleviating or curing diseases. We also help provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. For these endeavors, we focus on developing and successfully commercializing innovative products and solutions based on scientific knowledge.

Bicoll is an expert in bioactive plant-derived small molecules with outstanding expertise in high-tech natural product chemistry and validated experience in medicinal chemistry. Currently Bicoll focuses on two main fields such as neurodegenerative disorders (primarily, epilepsy) and longevity. In both of the fields it develops own preclinical candidates.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin.

BioGenes is a full-service provider of customized immunoassay and antibody development, with a strong commitment to quality and service. Founded in 1992 and headquartered in Berlin, Germany, BioGenes is a recognized partner serving more than 600 customers in 40 countries. The company maintains long-term relationships with global pharmaceutical, biotech companies, CMOs and in vitro diagnostic firms. BioGenes provides highly customized solutions for the quality control of biological products, from drug discovery and drug development to the manufacturing of biologicals, as well as for diagnostic purposes.

 The company specializes in sophisticated custom monoclonal, polyclonal and anti-idiotypic antibody development and has a proven track record in the development, optimization, pre-validation and production of highly sensitive and robust ELISAs and host cell protein (HCP) assays. Furthermore, BioGenes offers the enhanced generic 360-HCP ELISA kits and supports customers with a comprehensive range of analytical services.

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html

Your partner for the use of particularly sustainable and future-proof plastics in medical technology, pharmaceutical packaging and laboratory products. We help you to replace fossil-based plastics with renewable, recyclable and biologically safe materials. We supply you with the right materials for this purpose. With ISO 13485 quality management and tested biological safety in accordance with ISO 10993. Our broad network also supports you with upstream and downstream challenges such as the development and production of your sustainable medical, pharmaceutical or laboratory product.

Booster Therapeutics is pioneering a new class of medicines that activate proteasomes (the cell’s natural quality control machinery) to treat a range of complex indications. The company is developing a multi-disease pipeline, with an initial focus on neurodegenerative diseases associated with impaired proteasome function.

Breakpoint Therapeutics is developing targeted cancer therapies that modulate DNA damage response (DDR) pathways. Through precise interference with DNA repair, our drug candidates are designed to kill cancer cells without harming healthy cells. We leverage new insights and the concept of synthetic lethality to increase the therapeutic window and achieve better outcomes for patients with therapy-resistant and hard-to-treat cancers.

Capnopharm develops aerosol-based chemotherapies and immunotherapies for peritoneal and pleural cancer patients. Our science relies on a growing body of evidence around PIPAC™ (Pressurized Intraperitoneal Aerosol Chemotherapy), a minimally invasive aerosol drug delivery system. PIPAC™ provides numerous avenues for research and development in oncology – from re-formulation of existing chemotherapy drugs to next-generation drugs involving Nanoparticles, DNA, mRNA or Immunotherapeutics. Together with our pharmaceutical clients, we explore drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

ChemCon GmbH - Your Good Manufacturing Partner! ChemCon is a contract development and manufacturing organization (CDMO) located in Freiburg, Germany. We manufacture drug substances (injectable, ophthalmic, oral, topic grade) and ultra-pure chemicals to your specifications. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds, polymers, and highly potent or controlled substances. ChemCon’s facilities are optimized for the production of small to medium quantities (g to multi 100 kg per year). This is particularly interesting if you are sourcing APIs for clinical trials or commercial applications (i.e., orphan diseases, oncology, or emergency care) with a low annual demand. We also manufacture excipients, provocation substances, dietary trace elements, diagnostics, delivery agents, or reference standards. Your project will be under one roof from synthesis & process development/establishment all the way to commercial cGMP manufacturing, including full documentation, quality control and regulatory support. We also offer external analytical services, independent from production services. ChemCon looks back on an outstanding inspection history by both the FDA and European health authorities. Impressum: ChemCon GmbH, Engesserstr. 4b, 79108 Freiburg i.Br. Phone.: +49 (0)761-5597-0; E-Mail: Info@chemcon.com CEO/President: Dr. Raphael Vogler Commercial register: HRB 5973 Court of registration: Freiburg VAT Reg. No: DE812753447

CPL Sachse produces APIs for human and veterinary use. We manufacture APIs under cGMP for (pre-)clinical development and market supply up to ≤ 50 kg scale. The company has been successfully inspected multiple times by EMA (LaGeSo) and FDA. The following compounds are available from us under a GMP certificate from our local authority: - Anagrelide, - Atipamezole, - Clenbuterol (CEP), - Detomidine (CEP), - Medetomidine, - Methacetin(13C), - Nabilone - Phenoxybenzamine. Further APIs as well as reference standards for APIs and impurities are available on request. Moreover, we carry our route scouting for NCEs and develop and validate processes as well as analytical methods required to test the APIs and the subsequent drug products. Furthermore, we offer stability tests according to ICH guidelines. The company introduced and offers Maximator® HPE. This continuous high pressure extruder (HPE) allows rapid and reproducible large-scale production of unilamellar liposomes. Finally, we offer all regulatory services required for the preparation and submission of a pharmaceutical dossier (for APIs and drug products).

At ColVisTec, we work with the world's leading manufacturers in the paint, pharmaceutical, plastics, and chemical industries. Our team of highly knowledgeable engineers and scientists support them with a reliable and industry-ready inline UV-Vis spectroscopy.​ ​ By adding inline UV-Vis spectrophotometry devices onto the assembly line, we can measure the production output in real-time. In addition, it opens fantastic opportunities for productivity as well as quality gains, leading to a huge stand-alone benefit for your factory when implemented into the context of digitalized manufacturing: Industry 4.0. Our technology can be customized for a wide variety of processes, allowing flexible hardware configurations, offering data output in different formats, and excellent integration with the software solutions already in place. We take pride in our extensive customer support and provide a full menu of training options to secure a smooth transition from off-line measurement to fully automated inline solutions. ​ From our headquarters in Berlin, Germany, we support our product line worldwide and work in close cooperation with other process machinery manufacturers to provide complete solutions when customers are in the market for new plants. Most often our technology is fitted to the existing manufacturing facilities, boosting their productivity and quality. We don’t see ourselves as suppliers of hardware, our aim is to provide unique solutions that are specifically required by your process. ​ Our company was founded in 2009 and is now co-funded by the Horizon 2020 program of the European Union.

Analytik Jena is a leading global supplier of analytical measurement technology in the field of molecular biology as well as liquid handling and automation technology. Whether in the fields of chemistry, pharmaceuticals, medicine and life science, food safety, agriculture or environmental analysis - Analytik Jena offers standard-compliant applications for routine analysis as well as for special tasks. Precision, reliability, easy handling and comprehensive service are the top priorities in the development of laboratory analysis products. Analytik Jena is part of the Swiss Endress+Hauser Group. Visit our YouTube profile for moving footage >>> https://www.youtube.com/@analytik-jena

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

The Eckert & Ziegler Group is one of the world's largest providers of isotope technology for medical, scientific and industrial use. The core businesses of the Group are: cancer therapy, industrial radiometry and nuclear-medical imaging. The two business segments are Medical and Isotope Products.

Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-out of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Eisbach will beat cancer at its own game.

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

FundaMental Pharma - We are an early stage start-up company having laid the foundation for the development of a class of neuroprotective small molecules with an entirely new pharmacological mode of action. FMP neuroprotectiva are expected to be broadly applicable in the treatment of currently untreatable human neurological conditions. These include vascular brain damage and dementia, traumatic brain injury, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Huntington’s disease (HD), retina degeneration, and brain damage caused by virus or parasite infections.

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America and the US. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of € 1.8 bn. More Information on www.grunenthal.com Jobs & Career: http://careers.grunenthal.com/ Imprint: https://www.grunenthal.com/en/footer-links/imprint Privacy: https://www.grunenthal.com/en/footer-links/privacy-statement-social-media This company profile is managed by Global Communications. In our commitment to transparency and the principles outlined in our digital ethics charter, Grünenthal wishes to inform you that generative artificial intelligence technologies are occasionally used to enhance content on this channel. Each content piece has been reviewed and edited by a team member before publication to ensure accuracy.

HepaRegeniX GmbH is a clinical-stage biotechnology company developing novel therapies for the treatment of acute and chronic liver diseases.

HMNC Brain Health - We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development.

Isarna Therapeutics is a clinical stage biotech company, headquartered in Munich, Germany. Isarna develops ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in the pathogenesis of retinal disease. Current therapies – approved and pipeline products – mostly target the edema, with several anti-VEGFs approved or in development offering only minor improvements over current SOC. While anti-VEGF is a very effective therapy – it does not stop the disease progression of retinal pathologies like w AMD. Patients progress to late-stage disease despite effective anti-edema therapy – and thus develop fibrosis. TGF-b is a key driver of fibrosis, so blocking the production of this molecule intracellularly, using elaborated antisense molecules, promises to be a game-changer in retina therapy. Animal data show comparable efficacy of ISTH0036 to block neovascularization as anti-VEGF – with the added benefit of suppressing fibrosis. This MOA could be an effective long-term treatment in several retinal pathologies including the blockbuster-indications wAMD, DME, RVO, with a significant upward potential in dry AMD. A Phase 1 study showed excellent safety, Isarna Therapeutics is currently preparing a Phase 2a study in wet AMD and in DME/DR. Isarna is led by a highly experienced management, the COO, Rene Rückert, MD, MBA led at Bayer/Novartis the global development of both approved blockbuster drugs for retinal diseases – Eylea and Lucentis. The CMO, Prof. Marion Munk, MD, PhD is a leading global retina specialist. Isarna is open to discuss future partnering for the development and is seeking investors to finance the clinical development and growth of the company.

We are the Peptide Experts! JPT has a large peptide synthesis capacity, providing over 1 million peptides per year. We offer all possible peptide modifications such as macrocyclic peptides, phosphorylated peptides, labeled and tagged peptides, radioligands, isotope labeling and more. Made in Germany Global Support More than 20 Years of Expertise Ethical, Environmental & Health Standards Portfolio: Custom Peptides Our patented technologies in peptide libraries, pools, microarrays, and micro-scale synthesis set us apart as a leader in the field. From micro to large-scale synthesis, our state-of-the-art labs in Germany deliver peptides tailored to your needs. Modified Peptides We produce modified peptides such as long and stapled peptides, dyes, labeled and biotinylated peptides, PTMs, unique building blocks, conjugations, macrocyclic peptides and more. PepMix Peptide Pools Peptide pools for antigen-specific T-cell stimulation in immune monitoring, assay control, cell therapy development, T-cell expansion etc. In addition to custom PepMix peptide pools we have more than 500 PepMixes in stock, for example: Control Pools: CEFX, CEF, Actin, CMV pp65 … Viral Proteins of EBV, SARS-CoV-2, CMV, VZV, HPV … TAA: Prame, NY-ESO-1, MART-1, MAGE A … Clinical Peptides & Pools Our resulting Clinical Grade Peptides have been approved for a variety of clinical applications including immunotherapy and vaccine development, immune monitoring, and clinical proteomics. Please visit our website for more information! JPT Peptide Technologies GmbH Management: Aurélien Claeyssen, Jens Holstein, Dr. Sierk Poetting Volmerstr. 5 D- 12489 Berlin T: +49 30 6392 5500 peptide@jpt.com https://www.jpt.com/ Registration Court: Berlin / Amtsgericht Charlottenburg, HRB 92692 VAT identification number: DE 814044483 Imprint: https://www.jpt.com/support-contact/corporate/imprint/ Privacy Policy: https://www.jpt.com/support-contact/corporate/privacy-policy/

Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.

Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss

MerLion Pharmaceuticals - We are a bio-pharmaceutical company focused on the development of novel antibiotics to combat the evolving threat of bacterial infections in humans and animals. MerLion Pharmaceuticals is located in Berlin-Buch, Germany and manages the non-clinical and clinical development as well as active pharmaceutical ingredient and drug product development and manufacturing. Our pipeline includes the antibiotics finafloxacin and friulimicin.

MODAG focuses on research and development of therapeutics and diagnostics for neurodegenerative diseases. It is a privately held company located at the Hochtechnologiepark Wendelsheim, Germany with additional Research & Development facilities in Munich and Göttingen. MODAG’s innovative approach offers a unique combination of early diagnosis and targeted disease-modifying therapies for severe neurological disorders. MODAG´s collaborations with top-tier US and European research institutions, combined with the interdisciplinary research and development expertise of the founder´s and the management team, provide ideal conditions for the accelerated implementation into clinical applications. Built upon an extensive portfolio of patented active compounds, MODAG is developing a new oligomer modulator for Multiple System Atrophy (MSA) and other synucleinopathies such as Parkinson´s disease (PD) with the potential to deliver novel disease-modifying, first-in-class drugs with the potential to halt progression.

NanoTemper Technologies is deeply committed to the best customer experience. Central to this is a strong focus on high quality products made in Germany that enable researchers to easily, efficiently, and accurately perform protein characterization. With a broad offering of systems, software and consumables for evaluating binding affinities and protein stability, scientists in pharmaceutical, biotech or academic labs will find an optimized workflow, quality results and responsive customer support. Work with a deeply experienced and globally operating team, and realize the NanoTemper experience.

NMI TT Pharmaservices is a Contract Research Organization dedicated to provide experts services to customers in Pharma, Biotech and Academia. Our business is focused on high-quality services and R&D support, for preclinical drug discovery & development, drug mode of action studies, predictive toxicology, safety pharmacology, and biomarker screening. Our main competences are - Protein Profiling Services - Custom Cell Services - Electrophysiology Services NMI TT GmbH, a privately-held company founded in 2002, is a subsidiary of the NMI Natural and Medical Sciences Institute at the University of Tübingen, a private research foundation, with operations in Reutlingen and Berlin, Germany.

NOXXON is a biopharmaceutical company that specializes in drug development in the healthcare sector.

OMEICOS Therapeutics has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat mitochondrial dysfunction, inflammatory, cardiovascular and other diseases. Epoxyeicosanoids activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. The currently active PMD-OPTION Phase 2a clinical study is evaluating OMEICOS’ lead development program OMT-28 in patients with Primary Mitochondrial Disease.

No more data siloes. No more missed connections. Advanced chemical search and analysis made accessible to all. Unlock and extract insight for life sciences and chemistry. OntoChem enables your teams to consolidate and normalize all internal and external data from knowledge scattered across different documents, systems and geographical locations. OntoChem is part of Digital Science. Visit our website at ontochem.com

Origenis - We cure diseases with novel small molecule drugs where no drugs have been discovered yet. We create synergistic small molecule drug pipelines.

PEPperPRINT is an innovative biotech company from Heidelberg, Germany, and the leading provider of high density peptide and protein microarrays for antibody characterization or the fingerprint analysis of antibody responses from biological samples. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 200 peer-reviewed publications.

Phyton Biotech is the world's leader in pharmaceutical plant cell fermentation (PCF®) technology. A global supplier of high quality oncology actives via PCF, our products are registered in every major country in the world. With state-of-the-art facilities near Hamburg and Vancouver, we also offer comprehensive development services via PCF for plant-based actives, complex small molecules, and a variety of products used in the treatment of cancer and other serious illnesses.

Priavoid is a clinical stage drug development company based in Düsseldorf, Germany. Its therapeutic focus is on protein misfolding disorders in the area of neurodegeneration. Key component of Priavoid's technology is an anti-oligomeric or anti-prionic mode of action, that efficiently and effectively disassembles neurotoxic aggregates by using all-D-peptides.

Transforming proteins into pioneering drugs ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and delicate small molecules into pioneering drugs. ProJect Pharmaceutics adds value to client´s bio-pharmaceutical products by applying an innovative concept of development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized formulations and delivery systems for biologics that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products, biosimilars as well as "bio-betters" are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing. We offer: • predictive formulation analytics • formulation development including in-depth protein analytics • lyophilization process development and optimization • lyophilization in dual chamber prefilled syringe • development of liposomal formulations, producible by simple stirring • manufacturing of preclinical study material • technology-transfer including scale-up to GMP-manufacturer We deliver: • optimized formulations for biopharmaceuticals • tailored manufacturing processes and transfer to GMP manufacturing • development reports ready for submission to the authorities for registration

Rapid Micro Biosystems is an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. We are the trusted partner in quality control microbiology automation, enabling our customers to improve and save lives. This vision has been realized with the development of the Growth Direct® System. Our Growth Direct® platform automates and modernizes the antiquated, manual quality control microbiology testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line QC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. Our company values guide us in our vision: Customer Driven – We are committed to providing our customers with the highest quality products and services Respect – We welcome and embrace our differences to create a trusting environment Grit – We are determined to turn challenges into successes. One RMB – We operate as one team, committed to our shared purpose. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands.

About ratiopharm ratiopharm became known as the first generics company in Europe. Today, ratiopharm is a pharmaceutical brand with a broad portfolio of OTC and generic prescription medicines in several European countries. Including Germany, Austria, Spain and Finland. ratiopharm - a brand of Teva Since 2010, ratiopharm has been part of Teva Pharmaceuticals, a global leader in generics and biopharmaceuticals. As part of Teva, we benefit from access to innovative networks and high-quality, internally produced active ingredients. Access to medicines and health Every day, we work to ensure access to medicines and thus the supply of essential medicines to millions of people. We provide high-quality generics for nearly all indications and therapeutic solutions that are customized to the needs of our patients. We are convinced that quality can be offered at fair prices. And that not only helps individuals, but also makes a sustainable contribution to the performance and efficiency of the healthcare system.

Refoxy Pharma is a pre-clinical stage biotechnology company developing medicines for the treatment and prevention of aging and aging-associated diseases.

Rommelag is the inventor of blow-fill-seal technology (BFS) and the global market leader in the aseptic filling of liquids and semisolids with its bottelpack machines. Our machines are primarily used in the pharmaceutical, chemical, and food industries. Together with our customers, we develop innovative packaging solutions tailored precisely to the specific packaging task at hand. We built the first prototype bottelpack machine in 1962. Since then, we have continued gathering and sharpening our expertise in packaging solutions using BFS. We are delighted to say we now have customers in over 80 countries worldwide and more than 2,000 dedicated employees.

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company addressing high unmet medical needs in the areas of immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies for challenging or currently undruggable targets. With over 15 development programs focusing on targets in indications where antisense-based approaches have clear benefits over other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE´s immunoassays.

The highly experienced research team founding the STRATIFYER Molecular Pathology GmbH has developed techniques to analyze routine tumor material for sophisticated molecular analysis. A specialized process has been developed that guarantees fast and reliable assessment of prognostic and predictive gene signatures in mid-throughput fashion. This technology has been exploited for multiple years to enable in-depth genomic research accompanying large clinical trials. First pathology labs have been powered by STRATIFYER Molecular Pathology GmbH to integrate RNA expression profiling tests in clinical routine. The molecular STRATIFYER test systems shall enable physicians to optimize anti-cancer treatment at patient's initial diagnosis according to individual differences of the tumors.

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.

Topas Therapeutics is a clinical-stage biotechnology company transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology. Our antigen-coupled nanoparticle platform harnesses the tolerogenic power of the liver to treat autoimmune diseases. Our proprietary Topas Particles Conjugates target liver sinusoidal endothelial cells, a specific type of antigen-presenting cells highly effective at inducing T cell tolerance. With a technology adjustable to a broad spectrum of disease-relevant antigens, we have established a growing and advanced clinical pipeline to induce systemic tolerance. To learn more visit https://topas-therapeutics.com/

Treamid Therapeutics GmbH was founded in 2016 with the aim to develop new and innovative treatments for respiratory and inflammatory diseases. All our small molecules are under global patent protection. Our aim is to develop new drugs in the area of high unmet need for respiratory and inflammatory disease, supporting patients with new innovative and easily accessible medications. We are collaborating with well-renowned institutions and CROs in different fields of our research and development. We also have our own in vitro lab driving our research and developing new methods to further investigate our molecules in different disease areas.

Unlocking tRNA modifications for drug development

Who are we? vermicon AG from Munich, Germany, specializes in the development and production of sustainable solutions for the industrial microbiology. Since 1997, our actions are guided by the credo that the conventional limitations of microbiology have to be broken down in order to receive convincing solutions. Successful answers for microbiological challenges and a permanent implementation of these solutions into practice is what we strive for. What are we offering? PRODUCTS Detection systems and test kits for industrial customers. Handy and suitable for on-site application, fast and nevertheless highly specific results. Simple workflow. Microbiology in a standardized and industrialized shape. SERVICES
 Comprehensive analyses for microbiology – fast, reliable and flexible. Our technology allows us to deliver insights and results that cannot be achieved with conventional methods. MICROBIOLOGICAL CONSULTING 
A unique combination of microbiology and consulting. Break new ground with us! Even for national or international research projects, we are your reliable partner. We bring our great wealth of experience to bear in every new project and every new problem. A broad spectrum of technological options and a high innovative capacity guaranteed by a team of microbiologists and chemists allow us to always break new and exciting ground. Learn more about us – our corporate principles say it all: ...to provide unique and efficient solutions for microbiology ...to meet successfully microbiological challenges which no one has solved before.

Vivoryon is focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The mechanisms of action underlying our approach enables us to target a variety of disease areas with high medical need. With historic roots in diabetes research and development as well as neurodegenerative disorders, Vivoryon’s focus is now on applying our approach to developing medicines in inflammatory and fibrotic disorders.